A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

Laborértékek

• Participants who meet any of the following criteria will be excluded from the study:
  • Presence of EGFR gene mutation;
  • Pathological diagnosis of small cell lung cancer or mixed tumors with small cell components, large cell neuroendocrine carcinoma (LCNEC), or sarcomatoid tumors;
  • Have previously received any of the following treatments:
  • Have received > 4 cycles of adjuvant chemotherapy. Prior neoadjuvant therapy. Major surgery within 4 weeks prior to randomization (including surgery for the primary neoplasm, but excluding vascular access procedures), or expected to undergo major surgery during the study.
  • Use of Chinese herbal medicine with anti-tumor indications within 14 days prior to randomization.
  • Use of growth factor support therapy or have received a transfusion within 14 days prior to randomization.
  • Prior anti-tumor treatment with anti-PD-1, anti-PD-L1/2, anti-CD137, CTLA-4 modulators, or any other immunomodulatory agents.
  • Severe acute or chronic infection, including any active infection requiring systemic anti-infective therapy within 2 weeks prior to randomization;

• Participants must meet all of the following criteria:
  • Male or female, aged ≥18 and ≤75 years on the day of signing the Informed Consent Form (ICF);
  • Participants are able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures;
  • Pathologically confirmed non-small cell lung cancer (NSCLC) after surgery, with a clear histological type and a pathology report provided;